Appropriate Surveillance for Late Complications in Patients in Remission from Hodgkin Lymphoma

Department of Internal Medicine, Division of Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Current Hematologic Malignancy Reports (Impact Factor: 2.2). 06/2012; 7(3):200-7. DOI: 10.1007/s11899-012-0128-z
Source: PubMed


Once considered to be incurable, now most patients with the diagnosis of Hodgkin lymphoma (HL) survive and are cured of their disease. Although HL survivors are out living their disease, they continue to have increased morbidity and mortality compared to their age-matched and sex-matched peers in the general population. Late complications of their treatment are well documented and include cardiovascular diseases, pulmonary diseases, endocrine dysfunction and second malignancy. Research exploring appropriate surveillance for these complications is lacking. However, evidence to support surveillance is mounting and many are publishing consensus-based guidelines recommending surveillance for these anticipated complications. This review will summarize the most recent literature addressing the appropriate surveillance for late complications in patients in remission from HL.

3 Reads